{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:06:43Z","timestamp":1761512803926},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":2010,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/jto.0b013e3181d737e3","type":"journal-article","created":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T06:41:15Z","timestamp":1272350475000},"page":"841-845","source":"Crossref","is-referenced-by-count":6,"title":["Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"5","author":[{"given":"David R.","family":"Spigel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey F.","family":"Patton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Zubkus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Simons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Griner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Anthony","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181d737e3_bib1","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1200\/JCO.2008.17.7162","article-title":"Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib2","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(00)04644-4","article-title":"Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial [see comment]","volume":"357","author":"Georgoulias","year":"2001","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib3","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2003.06.099","volume":"21","author":"Gridelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib5","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1200\/JCO.2003.03.195","article-title":"Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group\u2013 EORTC 08975","volume":"21","author":"Smit","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib6","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib7","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1200\/JCO.2005.01.003","article-title":"Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status <\/= 70) and advanced non-small-cell lung cancer [see comment]","volume":"23","author":"Baka","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib8","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.1999.17.7.2081","article-title":"Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial","volume":"17","author":"Crino","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib9","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2004.10.576","article-title":"Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group","volume":"22","author":"Laack","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib10","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1200\/JCO.2005.13.953","article-title":"Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer","volume":"23","author":"Ma","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib11","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1200\/jco.2005.23.16_suppl.7257","article-title":"Final report of a phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors: second dosing schedule & response","volume":"23","author":"Melemed","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"3","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc 5"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib14","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2008.20.9114","article-title":"Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer","volume":"27","author":"Gronberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib15","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib16","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-07-5143","article-title":"Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer","volume":"14","author":"Ohe","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/annonc\/mdh105","article-title":"A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer","volume":"15","author":"Sculier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<855::AID-CNCR12>3.0.CO;2-R","article-title":"Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group","volume":"85","author":"Font","year":"1999","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib19","first-page":"3087","article-title":"A new cisplatin\/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study","volume":"22","author":"Rossi","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1097\/JTO.0b013e3181d737e3_bib20","doi-asserted-by":"crossref","unstructured":"Peng G, Zinner RG, Wang Y, et al. Comparison of Patient Outcomes Stratified by Histology Among Pemetrexed (P)-Treated Patients (pts) With Stage IIIB\/IV Non-Small Cell Lung Cancer (NSCLC) in Two Phase II Trials. Presented at the American Society of Clinical Oncology Annual meeting. Chicago, IL, 2008.","DOI":"10.1200\/jco.2008.26.15_suppl.8096"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641530513X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641530513X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T16:22:44Z","timestamp":1544545364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608641530513X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S155608641530513X"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181d737e3","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}